{"id":7314,"date":"2025-03-21T22:35:00","date_gmt":"2025-03-21T15:35:00","guid":{"rendered":"https:\/\/www.globenewswire.com\/news-release\/2025\/03\/21\/3047170\/0\/en\/IDEX-Biometrics-ASA-Interim-statement-of-financial-position-as-of-1-January-2025.html3047170"},"modified":"2025-03-21T22:45:53","modified_gmt":"2025-03-21T15:45:53","slug":"idex-biometrics-asa-interim-statement-of-financial-position-as-of-1-january-2025","status":"publish","type":"post","link":"https:\/\/cryptoinsider.asia\/vi\/idex-biometrics-asa-interim-statement-of-financial-position-as-of-1-january-2025\/","title":{"rendered":"IDEX Biometrics ASA: Interim statement of financial position as of 1 January 2025"},"content":{"rendered":"\n

IDEX Biometrics ASA (\u201cIDEX\u201d or \u201cCompany\u201d) released its preliminary financial statements for 2024 on 27 February 2025. Subsequently, on 11 March 2025, the Company announced its revised business strategy plan. The Company has reviewed its assets and business in view of this strategy. Certain equipment items have been written down and an obsolescence provision has been recognised on inventory, and other, minor adjustments have been made. The total effect for the IDEX Biometrics group on the consolidated result for 2024 and the consolidated net equity as of 31 December 2024 amounted to an increased loss of USD 1.6 million and lower equity by the same amount. This will be reflected in the annual financial statements for 2024 to be issued on 30 April 2025.<\/p>\n

In the separate parent company financial statements for the parent company, IDEX Biometrics ASA, an additional write-down on investments in subsidiaries amounting to USD 5.7 million was recognized. This adjustment does not impact the consolidated result or equity for the IDEX Biometrics group. <\/p>\n

An interim statement of financial position (Norwegian: Mellombalanse) for the parent company as of 1 January 2025 has been prepared for the purpose of the extraordinary general meeting on 11 April 2025 to consider the board\u2019s proposal to reduce the share capital. The interim statement of financial position is attached to this notice. Please refer to the separate notice of the extraordinary general meeting.<\/p>\n

For further information contact:<\/p>\n

Marianne B\u00f8e, Head of Investor Relations, Tel: +47 91800186<\/p>\n

Kristian Flaten, CFO, Tel: +47 95092322<\/p>\n

E-mail: ir@idexbiometrics.com<\/a><\/p>\n

About IDEX Biometrics:<\/p>\n

IDEX Biometrics ASA (IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market. For more information, visit www.idexbiometrics.com .<\/p>\n

About this notice:<\/p>\n

This notice was published by Kristian Flaten, CFO, 21 March 2025 at 16:35 CET on behalf of IDEX Biometrics ASA.  This information is subject to the disclosure requirements pursuant to the Norwegian Securities Trading Act section 5-12.<\/p>\n

Attachment<\/strong>\n<\/p>\n